HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Alivus Life Sciences Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Last Updated on: Aug 30, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 944.5 as of 29 Aug 15:30.
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 years.
  • The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 27019 crore on March 2024 . This represents a CAGR of 35.97% over 5 years.
  • The revenue of Alivus Life Sciences Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Glenmark Pharmaceuticals Ltd for the Jun '25 is ₹ 3290 crore as compare to the Mar '25 revenue of ₹ 3267 crore. This represent the growth of 0.7%.
  • The ebitda of Alivus Life Sciences Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Glenmark Pharmaceuticals Ltd for the Jun '25 is ₹ 283.73 crore as compare to the Mar '25 ebitda of ₹ 199.89 crore. This represent the growth of 41.94%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 46.97 crore over 9 quarters. This represents a CAGR of -44.00% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
  • The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
  • The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.

Alivus Life Sciences Ltd News Hub

News

Alivus Life Sciences to conduct AGM

Alivus Life Sciences announced that the Annual General Meeting(AGM) of the company will be...

Read more

12 Aug 2025 12:09

News

Alivus Life Sciences to declare Quarterly Results

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 1 Aug...

Read more

25 Jul 2025 11:06

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark Pharmaceuticals to conduct AGM

Glenmark Pharmaceuticals announced that the Annual General Meeting(AGM) of the company wil...

Read more

23 Aug 2025 11:07

News

Glenmark USA to launch Micafungin for Injection 50 mg/vial and 100 mg/vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Micafungin ...

Read more

19 Aug 2025 10:07

News

Glenmark Pharma's US arm to launch Micafungin injection in the US market

The product is bioequivalent and therapeutically equivalent to the reference listed drug M...

Read more

19 Aug 2025 12:11

News

Glenmark Pharmaceuticals announces board meeting date

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 1...

Read more

05 Aug 2025 18:06

News

Glenmark Pharmaceuticals Ltd spurts 1.22%, up for third straight session

Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting...

Read more

28 Jul 2025 13:05

News

Glenmark Pharmaceuticals receives revision in outlook on LT bank facilities

India Ratings and Research (Ind-Ra) has revised the Outlook on Glenmark Pharmaceuticals' (...

Read more

23 Jul 2025 18:35

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Alivus Life Sciences Ltd is 11,587 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 54,302 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd?

As of August 30, 2025, the Alivus Life Sciences Ltd stock price is INR ₹944.5. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹1924.25.

How do dividend payouts of Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions